Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Rica Capistrano I."'
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
A global, comprehensive and open access listing of approved anticancer drugs does not currently exist. Partial information is available from multiple sources, including regulatory authorities, national formularies and scientific agencies. Many such d
Externí odkaz:
https://doaj.org/article/86a2ecc5b4d547199735cd3630fa58de
Autor:
Rica Capistrano I., Sonz Paul, Ingrid Boere, Pan Pantziarka, Supriya Chopra, Remi A Nout, Gauthier Bouche
Publikováno v:
International Journal of Gynecological Cancer, 32(11):ijgc-2022-003585, 1377-1386. BMJ Publishing Group
ObjectiveDrug repurposing is an alternative development pathway that utilizes the properties of drugs approved for other diseases and builds on available safety and pharmacological data to develop the drug as a potential treatment for other diseases.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0b8922a96cebe64ec8a28013cc84605
https://doi.org/10.1136/ijgc-2022-003585
https://doi.org/10.1136/ijgc-2022-003585
Autor:
Hanne Vanpachtenbeke, Erik Fransen, Steven Staelens, Christel Vangestel, Luc Pieters, Rica Capistrano I, Sandra Apers
Publikováno v:
Phytomedicine: international journal of phytotherapy and phytopharmacology
Background Gloriosa superba L. (glory lily, Colchicaceae) contains colchicine, and related alkaloids such as 3- O -demethylcolchicine and its glycoside colchicoside. Previously the in vivo efficacy of a crude extract and a colchicine-poor / colchicos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::848ec8bd910d00ebc4794d504b9e71bb
https://doi.org/10.1016/j.phymed.2016.07.012
https://doi.org/10.1016/j.phymed.2016.07.012
Publikováno v:
Natural Product Communications; August 2017, Vol. 12 Issue: 8
Autor:
Pantziarka P; The Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium.; The George Pantziarka TP53 Trust, London, UK., Verbaanderd C; The Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium.; Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium., Sukhatme V; GlobalCures Inc., Newton, MA 02459 USA., Rica Capistrano I; The Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium., Crispino S; The Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium., Gyawali B; The Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium.; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115 USA., Rooman I; The Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium.; Oncology Research Centre, Vrije Universiteit Brussel, Brussels, Belgium., Van Nuffel AM; The Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium., Meheus L; The Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium., Sukhatme VP; GlobalCures Inc., Newton, MA 02459 USA.; Emory University School of Medicine, Atlanta, GA 30322 USA., Bouche G; The Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium.
Publikováno v:
Ecancermedicalscience [Ecancermedicalscience] 2018 Dec 06; Vol. 12, pp. 886. Date of Electronic Publication: 2018 Dec 06 (Print Publication: 2018).